NIH Reporter #BX-24-044

R&D Services for Novel Drug Development to Treat Right Ventricular Failure (RVF) at VA Medical Center San Francisco

This opportunity from the Veterans Affairs Medical Center San Francisco seeks research and development services for novel drug therapies targeting right ventricular failure (RVF): - Government Buyer: - Veterans Affairs Medical Center San Francisco (part of the U.S. Department of Veterans Affairs) - OEMs and Vendors: - No specific OEMs or vendors are named in the solicitation - Products/Services Requested: - Research and development services for the creation and validation of proprietary α1A-AR agonist drugs - Focus on developing novel compounds with intellectual property value - Efficacy testing of these compounds in reversing RVF - Development of a clinically viable α1A-AR agonist for therapeutic use - Unique or Notable Requirements: - Emphasis on proprietary drug development (novel α1A-AR agonists) - Clinical validation and demonstration of therapeutic potential for RVF - No specific product part numbers or quantities provided; the focus is on R&D services and outcomes - No detailed product line items or commercial off-the-shelf products are listed in the solicitation

Description

This project aims to develop and test a proprietary drug to treat right ventricular failure (RVF). It involves creating novel α1A-AR agonists with intellectual property value, testing their efficacy in reversing RVF, and developing a clinically viable α1A-AR agonist for potential therapeutic use. The project is funded by the Veterans Affairs and is scheduled from October 2024 to September 2026.

View original listing